Building on our achievements of treating hemophilia with inhibitors, we aim to be a trusted leader in hemophilia. Novo Nordisk has an industry-leading pipeline portfolio, addressing the many faces of hemophilia and with the potential to innovate the treatment options.
We recognize however that the medical products are only part of the response to hemophilia and our broader commitment to the hemophilia community is vital to realizing our ambitions.
To make our vision a reality, and improve outcomes for all people
with hemophilia, three core ambitions need to be realized.
Working with representatives from across the hemophilia community we
are continuously strengthening understanding. This has resulted in an
initiative launched in 2010. This largest multi-country psychosocial
survey conducted to date in hemophilia, HERO (Hemophilia Experiences,
Results and Opportunities) provides evidence of what it is like to
live with hemophilia. Novo Nordisk is furthermore also an active
partner on World Hemophilia Day.
We work to improve access to diagnosis, care and treatment primarily
through our commitment to the Novo Nordisk Hemophilia Foundation,
established in 2005, focusing on capacity building, awareness creation
as well as improving diagnosis and registries. The Foundation has an
impact around the world supporting healthcare professionals and
reaching out to people with hemophilia and allied bleeding disorders,
their family members and other community members.
Finally, we collaborate with patient and medical organizations around the world to advance treatment and care through innovation supporting education and advocacy and the development of new thinking. As an example, our Access to Insight program supports global hemostasis research with grants, scholarships and awards.